Department of Health

Their core work

The UK Department of Health (now the Department of Health and Social Care) is a government body that funds, shapes, and oversees public health policy across the United Kingdom. Within H2020, it channels national health priorities into European research — particularly in vaccine development, infectious disease preparedness, and public health surveillance. It brings regulatory perspective, population-level health data, and policy implementation capacity to research consortia, bridging the gap between laboratory science and real-world health system deployment. Its involvement signals government endorsement and access to national health infrastructure including biobanks, surveillance networks, and clinical trial sites.

What they specialise in

How they've shifted over time

In 2014–2018, the Department focused heavily on emergency infectious disease response — Ebola diagnostics, treatment trials, and filovirus preparedness dominated the portfolio, alongside foundational work on virus archives and biosafety infrastructure (EVAg, ERINHA2). From 2018 onward, the focus shifted toward systematic vaccine science (vaccinology infrastructure via TRANSVAC2, emerging zoonoses like Crimean-Congo fever), population-level biomonitoring (HBM4EU), and cross-cutting One Health approaches linking animal, food, and human health. This evolution mirrors the broader European pivot from reactive outbreak response toward preparedness-by-design and integrated health surveillance.

Moving from crisis-driven infectious disease response toward building permanent European vaccine and health surveillance infrastructure — expect continued interest in pandemic preparedness and zoonotic disease prevention.

How they like to work

Almost exclusively a participant rather than a consortium leader — only 1 coordination out of 43 projects (Mofina, an Ebola diagnostics project under IMI2). This is characteristic of a government ministry: they contribute policy authority, regulatory expertise, and national health system access rather than leading the science directly. With 783 unique partners across 53 countries, they are a super-connector — their involvement in a project signals broad institutional endorsement and opens doors to UK health system data and clinical infrastructure.

Exceptionally broad network spanning 783 unique consortium partners across 53 countries, making them one of the most connected health organizations in H2020. Their partnerships span academic institutions, pharmaceutical companies (through IMI2 projects), public health agencies, and research infrastructures across Europe and globally.

What sets them apart

As a national government health ministry participating directly in H2020 research, the Department of Health occupies a rare position at the intersection of health policy, regulatory authority, and scientific research. Unlike universities or research institutes, they bring the ability to translate project findings into national health policy and access to population-scale health data. For consortium builders, their participation adds governmental credibility and a direct pathway from research results to policy implementation in one of Europe's largest health systems.

Highlights from their portfolio

• CONCERT
  Largest single grant at EUR 2.08M — a European Joint Programme integrating radiation protection research across the continent.
• Mofina
  Their only coordinated project — a mobile Ebola nucleic acid test developed under IMI2, showing capacity to lead when the application is diagnostics deployment.
• HBM4EU
  Major pan-European human biomonitoring initiative (EUR 868K) linking chemical exposure data to health policy — exemplifies their bridge role between science and regulation.